Exosome Therapy Market

Exosome Therapy Overview

The global exosome therapy market is estimated to grow from USD 32 million in 2029 to reach USD 382 million in 2035 and USD 1,405 million by 2040, representing a higher CAGR of 41.1% during the forecast period.

To learn more about this report, request a free sample copy

In  recent years, therapies utilizing extracellular vesicles have garnered significant attention among the industry stakeholders for the treatment of diverse indications, primarily owing to the various benefits offered by them, including target specificity, enhanced tissue regeneration, and reduced inflammation and chronic pain. Over time, various research studies have demonstrated the potential of exosomes (membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications.

Currently, both industry and non-industry players are attempting to develop exosome therapeutics for disease management, some of which are already in clinical trials. Moreover, post the onset of the COVID-19 pandemic, there has been a steady increase in the investigational new drug (IND) applications filed for exosome therapy. In a recent review of more than 200 studies evaluating mesenchymal stem cell (MSC) derived exosomes for preclinical use, the exosomes demonstrated benefits in more than 70% of studies. 

Key Market Insights

The “Exosome Therapy Market - Distribution by Type of Therapeutic, Target Indication, Therapeutic Area, Route of Administration and Geography: Industry Trends and Global Forecasts, till 2040” report features an extensive study of the current market landscape, market size and future outlook for the companies involved in developing exosome therapy. The market report answers many key questions related to this industry. report features an extensive study of the current market landscape, market size and future outlook for the companies involved in developing exosome therapy. The market report answers many key questions related to this industry.

Exosome Therapeutics Market Landscape: Cancer Targeted Exosome Therapeutics Making Headway into the Pipeline

The exosome therapy market is presently growing at a significant pace among the dynamic sectors of pharmaceutical industry. At present, the pipeline features close to 120 therapeutic candidates, and this number is anticipated to grow further in the forecast period. More than 40% of the total number of drugs are in clinical stage of development. Of the total candidates, seven exosome therapies, including EXOMSC-COV19 (Dermama Biotech Lab), Dex2 (Gustave Roussy Institute), SF-MSC-EX (Osmangazi University), are currently being evaluated in the advanced clinical stages of development. 

Further, around 30% of the exosome therapeutics are being developed for treatment of cancer. Exosome based therapy for cancer is a novel approach and the drugs are currently in early stages of development. Breast cancer, lung cancer, melanoma and colon cancer are amongst some of the oncological indications where exosomes are being tested as delivery vehicles for targeted therapy. 

Exosome Therapy Developer Analysis: Both Pharmaceutical Companies and Academic Institutes are Active in the Exosome Therapeutics Market

Over time, more than 60 pharmaceutical companies and academic / research institutes have undertaken various initiatives to develop effective exosome therapies against multiple target indications. Moreover, multiple collaborations have been inked between both industry and non-industry players in order to advance the efforts in research and development of various pipeline candidates, over the past decade. In one such agreement signed in June 2022, Coya Therapeutics in licensed an exosome engineering technology from Carnegie Mellon University. The company gained worldwide rights to the exosome polymer hybrid technology that allows targeted delivery of the exosomes carrying drug of interest. Their first exosome therapy, COYA 206, based on this in licensed technology is currently in early research.

Venture Capitalists Are Supporting the Exosome Therapy Companies, though the Financing Rounds Have Been Small

In the last five years, capital investments worth around USD 500 million have been made by strategic investors for the research and development of exosome therapeutics. These funds have been raised through 35 number of instances, equating to an average of USD 16 million per funding round. In the most recent instance, Mantra Bio announced a USD 9 million Series A-2 round in January 2023. The company is developing targeted exosome therapeutics for ophthalmology and infectious disease.

Adoption of Novel Technologies to Meet the Challenges in The Exosome Therapeutics Industry

Despite the numerous benefits offered by exosome therapies, developers often face concerns related to the weak therapy preparations, bacterial infections, and contamination with non-exosomal components. Additionally, the heterogeneous nature of such extracellular vesicles (EVs) is one of the major challenges faced during the quantification and characterization of the required EVs from a diverse population of cells.   In order to mitigate the aforementioned challenges, novel technologies are being adopted by several stakeholders.  

Exosome Therapy Market Size

The exosome therapy market is estimated to be valued at USD 32 million in 2029. The market is projected to grow at a CAGR of 41.1%, with anticipated release of a number of therapies during the forecast period. In terms of route of administration, the market is likely to be driven by exosome therapeutics designed for intra-ocular administration. Further, in terms of therapeutic area, majority share of the revenues is expected to be generated by ophthalmic diseases. Specifically, in terms of geography, the exosome therapeutics market in Asia-Pacific is likely to grow at a significant pace, in the long term.

The factors contributing to the growth of exosome therapeutics market include increasing disease burden, rise in research and development activities for exosome therapeutics, and government funding for the production of exosome therapy. Moreover, the growth potential in the emerging economies will bolster the exosome therapeutics market growth during the forecast period.

Recent Developments: Drug Failures and Companies Filing for Bankruptcy Are Restraining the Exosome Therapy Market Growth

In March 2023, one of the well-known companies in the exosome therapy industry, Codiak BioSciences filed for bankruptcy. The company had two clinical stage exosome therapy and a preclinical stage molecule targeting cancer. According to Codiak BioSciences, the company did not have sufficient funds to carry forward the development of the molecules. This instance also reflects upon the smaller amount of funds that the developers are able to raise, which may not be sufficient once the pipeline moves into clinical trials.

Additionally, seven exosome therapeutics under development against various indications, primarily cancer, have been withdrawn due to limited or no patient enrollment, non-adherence to dosage regimen and financial constraints. In absence of availability of sufficient funds, the exosome therapy market is likely to witness events that can restrain the market growth.

Key Exosome Therapy Companies

The key companies engaged in this market (which have also been capture in this report) include Cellular Biomedicine Group, Coya Therapeutics, Curexsys, EV Therapeutics, Evox Therapeutics, ExoCoBio, ILIAS Biologics, Rion and SHIFTBIO. This market report includes an easily searchable excel database of all the companies and academic institutes developing exosome therapy.

Recent Developments in Exosome Therapy Market

Several recent developments have taken place in the field of exosome therapy market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In February 2026, MDxHealth announced the acquisition of Exosome Diagnostics from Bio-Techne, bolstering its exosome-based diagnostic capabilities in prostate cancer testing.
• In February 2026, PrimeGen US agreed to merge with DT Cloud Star acquisition in a ~$1.5B SPAC deal, supporting expansion of advanced cell and exosome-related therapies.
• In January 2026, Unicorn Bioscience announced  FDA approval of zero exosome products for therapeutic use, highlighting ongoing enforcement against non-compliant providers and emphasis on IND clinical trials for legitimacy amid $58.1B market growth.
• In September 2025, mdxhealth closed the acquisition of Exosome Diagnostics from Bio-Techne for $15 million total consideration, including the ExoDx Prostate test, CLIA-certified lab, and related assets.
• In October 2025, EVerZom raised €10 million in a funding round with an aim to develop exosome-based biotherapies targeting inflammatory diseases, enabling initiation of clinical development and advancement of their pipeline programs.

Scope of the Report

The market report presents an in-depth analysis, highlighting the diverse capabilities of players engaged in this industry, across different geographies as defined in the below table:

Key Report Attributes	Details
Forecast Period	Till 2040
Market Size 2029	USD 32 Million
Market Size 2040	USD 1,405 Million
CAGR (Till 2040)	41.1%
Type of Exosome Therapeutics	Allogenic, Autologous
Target Disease Indications	Degenerative Meniscal Injury, Dystrophic Epidermolysis Bullosa, Fistula Perianal, Retinitis Pigmentosa
Therapeutic Area	Dermatological Disorders, Musculoskeletal Disorders, Ophthalmic Disorders
Type of Formulation	Liquid, Aerosol
Route of Administration	Fistula Tract, Intra-articular, Intra-ocular
Geographical Regions	North America, Europe, Asia-Pacific and Rest of the World
Key Companies Profiled	Coya Therapeutics, Evox Therapeutics, Curexsys, EV Therapeutics, SHIFTBIO
Customizatiion Scope	15% Free Customization Option
PowerpPoint Presentation (Complimentary)	Available
Excel Data Packs	Market Landscape Analysis, Company Competitiveness Analysis, Patent Analysis, Recent Developments, Market Forecast and Opportunity Analysis

Amongst other elements the research report includes:

• General introduction to exosomes, types of extracellular vesicles and their origin, secretion, and type of membrane. In addition, it provides information on the development process of exosomes and details on applications of exosomes, mechanism of different therapies, along with the advantages, risks associated with exosome therapy and the future perspectives.
• A detailed assessment of the current market landscape of exosome therapeutics, based on several relevant parameters, such as phase of development (clinical and preclinical), technology platform (DeliverEXTM platform, iPSC Platform, engEx™ Platform, mTEV Platform, PEP Exosome Technology and others), type of payload (protein, biologics, RNA, vaccine, antisense oligonucleotide, DNA / protein and AAV capsids), target disease indication (s) (COVID-19, acute respiratory distress syndrome, skin regeneration, cancer and others), therapeutic area (oncological disorders, dermatological disorders, neurological disorders, infectious diseases, rare disorders, autoimmune disorders and respiratory disorders and others), biological target, route of administration (intravenous, oral, subcutaneous, intratumoral, nasal and others), type of therapy (monotherapy and combination therapy), combination drug, line of treatment and dosing frequency. In addition, it provides details on the companies engaged in the development of exosome therapeutics, along with information on their year of establishment, company size and location of headquarters.
• Elaborate profiles of the key exosome therapeutics companies, with maximum number of therapeutic programs in their pipeline. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio and a section on recent developments and an informed future outlook.
• Elaborate drug profiles of the key exosome therapy in the highest phase of development. Each profile features a brief information on product portfolio and clinical trial information including study title, study detail, status of trial, phase of development, trial location, patient enrollment, study start and end date.
• A detailed analysis of completed and ongoing clinical trials of various exosome therapeutics, based on different parameters, such as trial status, trial registration year, type of sponsor / collaborator, study design, and number of patients enrolled. In addition, the chapter highlights year-wise trend of completed and recruiting trials, age group of the patients enrolled, active industry and non-industry players and location of the trials.
• An in-depth analysis of academic grants that have been awarded to various research institutes for projects related to exosome therapeutics, during the period, since 2017, based on several parameters, such as year of grant awarded, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded).
• A detailed analysis of the global events attended by the exosome therapy developers, based on several relevant parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated department of participants, and active speakers (in terms of number of events).
• An analysis of the partnerships that have been established in this industry since 2017, covering instances of research agreement, licensing agreement, manufacturing agreement, product development and commercialization agreement, merger / acquisition, and other relevant deals.
• A detailed analysis of the various investments made since 2017, including grant / award, seed financing, venture capital financing, IPOs, secondary offering, debt financing, other equity, in  companies focused on the development of exosome therapeutics.
• An analysis of start-ups / small companies engaged in the development of exosome therapeutics, based on parameters, such as pipeline strength, pipeline maturity, financial support, number of investors, partnership activity and start-up health indexing.
• A case study highlighting the companies engaged in offering exosome development and manufacturing services along with the information on their year of establishment, company size, location of headquarters, types of service(s) offered (isolation, characterization, purification, chromatography, engineering, targeted delivery, diagnostic biomarker, and quality control), method of isolation, method of purification, method of characterization, method of exosome manufacturing (engineering and targeted delivery), scale of operation (discovery / research, pre-clinical, clinical or commercialized) and scalability (small, mid-sized or large).
• An in-depth analysis of exosome therapeutics that failed to progress to later stages of clinical development, based on various relevant parameters, such as trial status of discontinuation, target disease indication(s), route of administration and type of sponsor.

One of the key objectives of the market report was to identify the primary growth drivers and estimate the future growth opportunity associated with exosome therapy market in the mid to long term. Based on various parameters, such as historical sales, target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the forecast period 2029-2040. Our year wise projections of the current and forecasted opportunity within the exosome therapeutics market have further been segmented across type of therapeutic (allogeneic and autologous), target disease indication(s) (degenerative meniscal injury, dystrophic epidermolysis bullosa, fistula perianal and retinitis pigmentosa), therapeutic area (dermatological disorders, musculoskeletal disorders, ophthalmic diseases and rectal disorders), route of administration (fistula tract, intra-articular and intra-ocular), geography (North America, Europe and Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the market report were influenced by discussions held with several stakeholders in exosome industry. The research report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company / organization names):

• Chief Business Officer, Small Company, US
• Chief Business Officer, Mid-sized Company, South Korea
• R&D and Innovation Manager, Very Small Company, Portugal

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is exosomes therapy?

Answer: Exosomes therapy is a novel medical approach to deliver therapeutic molecules to selected cells in the body utilizing extracellular vesicles.

Question 2: What are the risks of exosome therapy?

Answer: The potential side effects of exosomes therapy includes improper sterilization of exosome extract allowing bacterial growth in final preparations which leads to unsafe treatments.

Question 3: What is the anticipated exosome therapy market size?

Answer: The global exosome therapeutics market is anticipated to be worth USD 1404.7 billion in 2040.

Question 4: What is the exosome therapy market growth (CAGR)?

Answer: The exosome therapy market is expected to grow at a CAGR of 41.1% during the forecast period till 2040.

Question 5: Which companies are leading the exosome therapeutics market?

Answer: The key companies engaged in exosome therapy market (which have also been capture in this report) include Cellular Biomedicine Group, Coya Therapeutics, Curexsys, EV Therapeutics, Evox Therapeutics, ExoCoBio, ILIAS Biologics, Rion and SHIFTBIO.